🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06863727
Recruiting Observational

The Beijing Longitudinal Disability Survey in Community Elderly

NCT06863727 · tracked via the Priya Life Science China tracker
Sponsor
Xuanwu Hospital, Beijing
Phase
Observational
Started
2023-08-07
Last updated
2025-03-07

Condition(s) studied

AgeingDisabilityCognitive ImpairmentFrailtyIntrinsic Capacity

Study summary

The goal of this observational study is to establish the prospective cohort of the Beijing Longitudinal Disability Survey in Community Elderly (BLINDSCE) to explore the high-risk factors and preventive interventions for disability and cognitive impairment among community-dwelling adults aged 65 years and over. The main question it aims to answer is:

* What are the high-risk factors able to predict the incidence and advance of disability and cognitive impairment in community-dwelling adults aged 65 years and over?
* What are the categories of function and cognitive performance trajectory in community-dwelling adults aged 65 years and over?

Eligibility

Sex
ALL
Min age
65 Years
Max age
Healthy volunteers
Accepted
Inclusion Criteria: * Community-dwelling adults aged 65 years or older who reside in Beijing. * Participants who sign an institutionally approved informed consent. Exclusion Criteria: * Participants with severe mental disorders and serious medical conditions preventing study investigation * Participants undergoing long-term professional treatment for physical function and cognitive functioning, such as hospitalization or rehabilitation.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Xuanwu Hospital, Capital Medical University Beijing China Recruiting

More Xuanwu Hospital, Beijing trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06863727 on ClinicalTrials.gov ↗ ← All trials in China